Navigation Links
InterMune to Conduct Conference Call and Webcast to Discuss Results of Triple Combination Study of ITMN-191
Date:1/9/2009

BRISBANE, Calif., Jan. 9 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will conduct a conference call and webcast on Monday, January 12 at 8:30 a.m. EST to discuss results from its Phase 1b, 14-day study of hepatitis C virus (HCV) protease inhibitor ITMN-191 (R7227) in combination with Pegasys(R) (interferon alfa-2a) and Copegus(R) (ribavirin) in patients chronically infected with HCV genotype 1. ITMN-191 is being developed in collaboration with Roche.

To access the live teleconference, dial 888-799-0528 (U.S.) or 973-200-3372 (international), conference ID# 80676348. To access the live audio webcast of the conference call, please log on to the investor relations page of the company's website at http://www.intermune.com. The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 80676348.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a research and development portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit htpp://www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. InterMune to Report Top-Line Results of Triple Combination Study of ITMN-191 in January 2009
2. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
3. InterMune Announces Start of 14-Day Triple Combination Study of ITMN-191 in Patients With Chronic Hepatitis C
4. InterMune Announces Receipt of Fast Track Designation for Pirfenidone From FDA
5. InterMune Announces Progress on Pirfenidone in IPF
6. InterMune Provides Additional Information on ITMN-191 (R7227) MAD Study Results
7. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
8. InterMune Announces Start of Phase 1b Trial of ITMN-191
9. InterMune Announces Approval of Clinical Trial Authorization for Phase 1b Trial of ITMN-191
10. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
11. Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... MARLBOROUGH, Mass., May 10, 2017 Hologic, Inc. ... financial results for the fiscal second quarter ended April ... (EPS) of $1.84 increased 666.7% compared to the prior ... business resulted in a significant gain, while non-GAAP diluted ... increased 3.2%, or 3.8% in constant currency terms.  Excluding ...
(Date:5/10/2017)... Md. , May 10, 2017 CSSi, ... solutions for the clinical research industry, is proud to ... www.CSSiEnroll.com . The new website features both enriched content ... user experience and enhances the company,s already well-established position ... industry. "After many months of hard ...
(Date:5/9/2017)... 9, 2017  Semler Scientific, Inc. (OTCQB: SMLR), ... to improve the clinical effectiveness and efficiency of ... first quarter ended March 31, 2017. ... customers to identify when preventive care options are ... like heart attacks or strokes occur," said ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... May 26, 2017 , ... Water damage to the flooring of several ... had left education officials with a number of critical issues to address before students ... to be accomplished with little or no disruption to class schedules. Second, the project ...
(Date:5/24/2017)... ... May 24, 2017 , ... In modern research, success depends ... instruments for research and understanding the basic principles that were designed to drive ... innovations in stereo microscopy for brightfield and fluorescence typically used in laboratories working ...
(Date:5/24/2017)... ... 24, 2017 , ... Altec Products, Inc., a leader in enterprise ... one-day technology conference in San Diego, CA. , At nVerge 2017, Altec will ... utilize and enhance their Sage ERP solutions by providing improved visibility and control to ...
(Date:5/24/2017)... ... May 24, 2017 , ... Drs. ... NY, who have now spent 10 years as clinical instructors for the reputable ... College of Dentistry. Through the program, private practitioners receive cutting-edge clinical training and ...
(Date:5/24/2017)... ... , ... Patients who want to receive cosmetic dentistry procedures such as Invisalign® ... for a consultation, with or without a referral. Dr. Bedich enjoys improving the appearance ... , Dr. Bedich offers a variety of cosmetic dentistry services at his practice that ...
Breaking Medicine News(10 mins):